210 related articles for article (PubMed ID: 26841010)
1. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma.
Ramakrishnan VG; Kumar SK
Cancer J; 2016; 22(1):7-11. PubMed ID: 26841010
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
3. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
4. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
7. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
8. An overview of pim kinase as a target in multiple myeloma.
Liu Z; Zhang Y; Guo Y; Wang H; Fu R
Cancer Med; 2023 May; 12(10):11746-11759. PubMed ID: 37162273
[TBL] [Abstract][Full Text] [Related]
9. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
Wang X; Blackaby W; Allen V; Chan GKY; Chang JH; Chiang PC; Diène C; Drummond J; Do S; Fan E; Harstad EB; Hodges A; Hu H; Jia W; Kofie W; Kolesnikov A; Lyssikatos JP; Ly J; Matteucci M; Moffat JG; Munugalavadla V; Murray J; Nash D; Noland CL; Del Rosario G; Ross L; Rouse C; Sharpe A; Slaga D; Sun M; Tsui V; Wallweber H; Yu SF; Ebens AJ
J Med Chem; 2019 Feb; 62(4):2140-2153. PubMed ID: 30715878
[TBL] [Abstract][Full Text] [Related]
12. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD; Farag SS
Expert Opin Investig Drugs; 2015 Feb; 24(2):261-71. PubMed ID: 25494820
[TBL] [Abstract][Full Text] [Related]
13. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
[TBL] [Abstract][Full Text] [Related]
14. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
16. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib: A new hope in the treatment of breast cancer.
Palanisamy RP
J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
[TBL] [Abstract][Full Text] [Related]
18. Pim kinase inhibitors: a survey of the patent literature.
Morwick T
Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
[TBL] [Abstract][Full Text] [Related]
19. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Qin A; Reddy HG; Weinberg FD; Kalemkerian GP
Expert Opin Pharmacother; 2020 Jun; 21(8):941-952. PubMed ID: 32164461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]